NCT03292328
Completed
Not Applicable
Yoga for Chemotherapy-Induced Peripheral Neuropathy in Breast and GYN Cancer Survivors: A Pilot Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Breast Cancer
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Enrollment
- 51
- Locations
- 2
- Primary Endpoint
- Change in treatment related peripheral neuropathy symptoms
- Status
- Completed
- Last Updated
- 11 months ago
Overview
Brief Summary
Some types of chemotherapy used to treat breast cancer can cause damage to nerves with symptoms like tingling, numbness, muscle weakness, and pain in the hands and feet that can last and can affect functioning. The purpose of this study is to find out the effects of yoga on reducing symptoms caused by such nerve damage.
Investigators
Eligibility Criteria
Inclusion Criteria
- •English-speaking
- •Age \>/= 18 years old
- •Survivors with a primary diagnosis of stage I-III breast, ovarian uterine, or endometrial cancer
- •Moderate to severe chemotherapy induced peripheral neuropathy, defined by symptoms such as numbness, tingling, or pain ratings of 4 or greater on a 0-10 numeric rating scale
- •Have completed neurotoxic chemotherapy, i.e. taxanes (paclitaxel, docetaxel) and platinum (carboplatin) at least 3 months prior to enrollment
- •If taking anti-neuropathy medications, they are on a stable regiment (no change in 3 months)
- •ECOG performance status 0-2
Exclusion Criteria
- •Participants with metastatic disease
- •Participants who are currently receiving physical therapy or practicing yoga for any reason
- •Control Group - Inclusion/Exclusion Criteria
- •Inclusion Criteria:
- •English speaking
- •Age \>/= 18 years old
- •Survivors with a primary diagnosis of Stage I-III breast, ovarian, uterine, or endometrial cancer
- •CIPN symptoms such as numbness, tingling, or pain ratings \< 2 on a 0-10 NRS scale
- •Have completed neurotoxic chemotherapy, i.e. taxanes (paclitaxel, docetaxel) and platinum (carboplatin) at least 3 months prior to enrollment
- •ECOG performance status 0-2
Outcomes
Primary Outcomes
Change in treatment related peripheral neuropathy symptoms
Time Frame: 8 weeks of the participants' most bothersome peripheral neuropathy symptom
Treatment related symptoms will be evaluated by using NCI CTCAE v4.0
Study Sites (2)
Loading locations...
Similar Trials
Completed
Not Applicable
Meridian Yoga on Chemotherapy-induced Peripheral Neuropathy in Breast Cancer PatientsCIPN - Chemotherapy-Induced Peripheral NeuropathyBreast CancerNCT05959811China Medical University Hospital80
Terminated
Not Applicable
Heading Off Peripheral Neuropathy With ExercisePeripheral Nervous System DisordersBreast NeoplasmsChemotherapyNCT00869804University of Nebraska19
Not yet recruiting
Not Applicable
CIPN and it's Impact on Quality of Life in Patients Receiving Platinum and TaxanesChemotherapy-induced Peripheral NeuropathyNCT05829967Assiut University60
Recruiting
Phase 4
Preventive Approach Using VenlafaxinePeripheral Neuropathy Due to ChemotherapyNCT05875610Mit Ghamr Oncology Center60
Completed
Not Applicable
Chemotherapy-induced peripheral neuropathy in cancer patients – A four arm randomized trial on the effectiveness of electro-acupunctureG63.1Polyneuropathy in neoplastic diseaseDRKS00004448Klinik für Tumorbiologie an der Albert Ludwigs Universität Freiburg60